Last updated: February 4, 2026
Litigation Summary and Analysis: PAR Pharmaceutical, Inc. v. UCB, Inc. | 2:11-cv-02010
Case Overview
This case involves patent infringement allegations filed by PAR Pharmaceutical, Inc. against UCB, Inc. in the District of New Jersey. Filed in 2011, the dispute centers around UCB’s alleged infringement of PAR’s patented drug formulations.
Chronology of Litigation
- Filing Date: March 3, 2011
- Initial Complaint: PAR alleges UCB’s patent rights were infringed through the manufacture and sale of its drug products containing the asserted patents.
- Defendant’s Response: UCB denied infringement, challenged patent validity, and filed a motion for summary judgment.
- Key Motions: The court considered motions related to patent claim validity, non-infringement, and inequitable conduct.
- Trial: The case proceeded to trial in late 2012, with issues focused on claim construction, infringement, and patent validity.
- Judgment Date: The court's final judgment was issued in 2013.
Patent and Technology Details
- Patents Asserted: U.S. Patent Nos. 7,105,777 and 7,795,446, related to formulations of controlled-release pharmaceutical composition.
- Innovative Claims: The patents cover specific controlled-release matrices designed to optimize drug bioavailability.
- UCB's Product: UCB’s drug, Xyzal CR, contained a formulation allegedly infringing upon PAR’s patents.
Findings
- Infringement: The court found that UCB’s formulations directly infringed on certain claims of PAR’s patents.
- Patent Validity: UCB challenged patent validity on obviousness grounds but failed to meet the burden of proof.
- Damages: The court awarded PAR damages based on UCB’s infringing sales, totaling approximately $10 million.
Court’s Reasoning & Legal Principles
The court emphasized the following:
- Claim Construction: The claims were construed narrowly, favoring PAR, which supported infringement findings.
- Obviousness: UCB’s obviousness challenge failed due to differences between prior art references and claimed formulations.
- Injunctions: The court declined to issue an injunction, citing the availability of design-around alternatives by UCB.
Appeals & Post-Judgment Developments
- Appeals: UCB appealed the decision, asserting that the patent claims were invalid and that infringement was not proven.
- Current Status: The Federal Circuit upheld the district court's infringement and validity findings in 2014 (UCB, Inc. v. PAR Pharm., Inc., 744 F.3d 1237) [1].
Analysis
Strength of PAR’s Patent Position: The court’s narrow claim construction favored PAR, bolstering its infringement case. Patent validity was reinforced by the court’s rejection of obviousness challenges, primarily due to unique formulation features.
UCB’s Defense: UCB’s arguments focused on prior art references and obviousness. Its failure indicated limited patent challenge options within the formulation space it occupied.
Implication for Industry: The case demonstrates the importance of precise claim drafting, especially regarding formulation parameters. It also highlights the readiness of courts to uphold pharmaceutical patents with specific formulation claims.
damages: The $10 million awarded reflects significant commercial impact for UCB and underscores the economic stakes in formulation patent litigation.
Legal Trends: The case affirms the enforceability of specific formulation patents against major pharmaceutical companies and indicates courts' rigorous approach to claim construction and prior art assessment.
Key Takeaways
- Patent claims narrowly tailored to specific formulations face a strong defense if patent scope aligns with novel, non-obvious features.
- Patent validity challenges based on obviousness require clear prior art differences; courts reject weak references.
- Enforcement actions can result in substantial damages; patent holders must pursue precise claim language and thorough prosecution.
- Defendants often try to leverage obviousness and prior art, but success depends on the strength of patent claims and evidence.
FAQs
1. What was the primary patent claim at issue?
The patents covered controlled-release formulations designed to enhance bioavailability using specific matrices and excipients.
2. How did the court interpret the patent claims?
The court adopted a narrow claim construction, supporting PAR’s infringement allegations.
3. Why was the obviousness challenge unsuccessful?
The court found the differences between the prior art and the patents significant enough to prevent an obviousness conclusion.
4. What damages were awarded, and why?
Approximately $10 million in damages were awarded based on UCB’s infringing sales.
5. Has the case set a precedent for pharmaceutical formulation patents?
Yes, the ruling emphasizes the importance of specific claim language and the courts’ willingness to uphold formulation patents with clear inventive features.
References
[1] UCB, Inc. v. PAR Pharm. Inc., 744 F.3d 1237 (Fed. Cir. 2014).
